NVIDIA (NVDA) recently announced that it will jointly invest $10 billion with Eli Lilly (LLY) over the next five years to build a joint laboratory in Silicon Valley, aiming to accelerate the application of artificial intelligence in the pharmaceutical industry. The facility is intended to more closely align Eli Lilly’s laboratory capabilities with global AI innovation hubs. Through this collaboration, both parties aim to leverage AI technology to revolutionize the current drug development process, which heavily relies on manual labor, physical experiments, and is characterized by lengthy cycles.
This significant investment reflects NVIDIA’s active exploration of new application areas for its products following a substantial increase in its financial strength. As the global leader in AI accelerator chips, NVIDIA, despite its dominance in this field, still has relatively concentrated revenue streams. The company views the healthcare and pharmaceutical industries as key incremental markets for its technology. Although the industry has begun using AI computing systems to propose new drugs or compounds, subsequent validation still heavily depends on traditional laboratories. NVIDIA believes that AI has the potential to automate a considerable portion of this work. The company’s Vice President of Healthcare Business stated that human efficiency is the primary bottleneck limiting laboratory speed.
The newly established joint laboratory will focus on helping AI engineers gain a deeper understanding of experimental equipment and scientific workflows, thereby optimizing computer and software systems to take on tasks originally performed by humans. Additionally, NVIDIA is expanding its AI models and agents for the healthcare industry, releasing them as open-source resources to allow external customization and use. In terms of ecosystem development, NVIDIA is collaborating with Thermo Fisher Scientific (TMO) to connect laboratory equipment to its DGX Spark AI computer for automated control of experimental activities. It is also working with Multiply Labs to train robots in mastering scientific workflows, laying the foundation for highly automated experimental facilities in the future.
This partnership is not the first between the two companies. In October last year, they announced a joint effort to build “the most powerful supercomputer owned and operated by a pharmaceutical company.” The system is deployed at Eli Lilly’s headquarters and is scheduled to be fully operational in the first quarter of this year. Industry insiders point out that the new collaboration will further propel Eli Lilly to the forefront of AI-powered drug discovery. However, the field as a whole remains in its early stages and has yet to achieve significant commercial breakthroughs. Eli Lilly stated that its employees will work closely with NVIDIA’s team to achieve seamless integration and access top-tier technological resources. The initial focus of the innovative laboratory will be on drug discovery and AI model development.
Higher expectations are also placed on NVIDIA’s business development. Some analysts note that if the company can maintain its current profit margin levels, achieve performance growth in line with analyst expectations, stabilize its valuation, and sustain growth in AI-related expenditures through 2027, its market capitalization could reach a significant level. According to the average forecast of Wall Street analysts, NVIDIA’s revenue for fiscal year 2027 could reach approximately $320 billion. Based on current price-to-earnings ratio estimates, its market capitalization could reach a substantial scale. Multiple industry forecasts indicate that spending growth in the field of artificial intelligence is expected to continue until 2030, providing a long-term backdrop for the sustained application and market expansion of related technologies.
